Sato et al. conducted a phase I clinical trial to investigate the feasibility and efficacy of immunoembolization using GM-CSF for metastatic hepatic uveal melanoma, with a particular emphasis on evaluating dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) [8,22]. This evidence concerns the gene CSF2 and uveal melanoma.